Advertisement

Permanent chemotherapy-induced alopecia: awareness and attitudes among health care providers

  • Jenna R. Stoehr
  • Cory Kosche
  • Jennifer N. ChoiEmail author
Original Article
  • 26 Downloads

Abstract

Purpose

Reports of permanent chemotherapy-induced alopecia (PCIA) are increasing in the field of oncodermatology, but there is a dearth of information regarding how it is recognized and managed by health care providers (HCPs) across different medical specialties (dermatology, oncology, and internal medicine).

Methods

A 25-question survey was designed to elicit general knowledge and awareness of PCIA, as well as attitudes about referral and treatment. Responses were collected via REDCap, a secure online application, and analyzed with descriptive statistics, chi-square, and ANOVA tests.

Results

There was a significant difference in the number of subjects who had heard of PCIA prior to starting the survey (Derm 79%, Onc 30%, IM 22%, p < 0.05). A larger percentage of dermatology and oncology HCPs knew the correct definition of the condition (alopecia persisting > 6 months) than IM (42% and 45% vs. 17%) and significantly more had encountered patients with the condition (47% and 45% vs. 17%). More providers in dermatology and IM knew how to diagnose PCIA compared with oncology (84% and 83% vs. 70%). Dermatology HCPs were the only participants who had attempted to treat patients with PCIA, and most providers believed that patients would accept similar types of treatment for PCIA. Dermatology HCPs were more likely to report higher confidence in their abilities to diagnose and manage PCIA than other providers.

Conclusion

The results of this survey identify knowledge gaps about PCIA among health care providers. Therefore, education and multidisciplinary engagement should be pursued in order to improve awareness, diagnosis, referral, and management of PCIA as part of survivorship care.

Keywords

Permanent chemotherapy-induced alopecia Oncodermatology Survey research Long-term effects of cancer treatment Survivorship 

Notes

Acknowledgments

REDCap is supported at Northwestern University Feinberg School of Medicine by the Northwestern University Clinical and Translational Science (NUCATS) Institute. NUCATS is supported, in part, by the National Institutes of Health’s National Center for Advancing Translational Sciences, Grant Number UL1TR001422. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions

All authors contributed to study conception and design. Data collection and analysis was performed by J. Stoehr. The first draft of the manuscript was written by J. Stoehr. All authors contributed to consequent versions and approved the final manuscript.

Compliance with ethical standards

Conflict of interests

The authors declare that they have no conflict of interest.

References

  1. 1.
    Tallon B, Blanchard E, Goldberg LJ (2010) Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 63(2):333–336.  https://doi.org/10.1016/j.jaad.2009.06.063 CrossRefPubMedGoogle Scholar
  2. 2.
    Chon SY, Champion RW, Geddes ER, Rashid RM (2012) Chemotherapy-induced alopecia. J Am Acad Dermatol 67(1):e37–e47.  https://doi.org/10.1016/j.jaad.2011.02.026 CrossRefPubMedGoogle Scholar
  3. 3.
    Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Lee HK, Park JH, Lee DY, Lacouture ME, Guallar E, Cho J (2019) Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist 24(3):414–420.  https://doi.org/10.1634/theoncologist.2018-0184 CrossRefPubMedGoogle Scholar
  4. 4.
    Tosti A, Piraccini BM, Vincenzi C, Misciali C (2005) Permanent alopecia after busulfan chemotherapy. Br J Dermatol 152(5):1056–1058.  https://doi.org/10.1111/j.1365-2133.2005.06469.x CrossRefPubMedGoogle Scholar
  5. 5.
    Miteva M, Misciali C, Fanti PA, Vincenzi C, Romanelli P, Tosti A (2011) Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. Am J Dermatopathol 33(4):345–350.  https://doi.org/10.1097/DAD.0b013e3181fcfc25 CrossRefPubMedGoogle Scholar
  6. 6.
    Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O, Guillot B, Romieu G, Bessis D (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23(11):2879–2884.  https://doi.org/10.1093/annonc/mds095 CrossRefPubMedGoogle Scholar
  7. 7.
    Prevezas C, Matard B, Pinquier L, Reygagne P (2009) Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 160(4):883–885.  https://doi.org/10.1111/j.1365-2133.2009.09043.x CrossRefPubMedGoogle Scholar
  8. 8.
    Machado M, Moreb JS, Khan SA (2007) Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplant 40(10):979–982.  https://doi.org/10.1038/sj.bmt.1705817 CrossRefPubMedGoogle Scholar
  9. 9.
    Freites-Martinez A, Shapiro J, van den Hurk C, Goldfarb S, Jimenez JJ, Rossi AM, Paus R, Lacouture ME (2019) Hair disorders in cancer survivors. J Am Acad Dermatol 80(5):1199–1213.  https://doi.org/10.1016/j.jaad.2018.03.056 CrossRefPubMedGoogle Scholar
  10. 10.
    Freites-Martinez A, Shapiro J, van den Hurk C, Goldfarb S, Jimenez J, Rossi AM, Paus R, Lacouture ME (2018) CME part 2: hair disorders in cancer survivors persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery. J Am Acad Dermatol.  https://doi.org/10.1016/j.jaad.2018.03.056 CrossRefGoogle Scholar
  11. 11.
    Ozoh OB, Awokola BI, Buist SA (2014) A survey of the knowledge of general practitioners, family physicians and pulmonologists in Nigeria regarding the diagnosis and treatment of chronic obstructive pulmonary disease. West Afr J Med 33(2):100–106PubMedGoogle Scholar
  12. 12.
    Jho HJ, Kim Y, Kong KA, Kim DH, Choi JY, Nam EJ, Choi JY, Koh S, Hwang KO, Baek SK, Park EJ (2014) Knowledge, practices, and perceived barriers regarding cancer pain management among physicians and nurses in Korea: a nationwide multicenter survey. PLoS One 9(8):e105900.  https://doi.org/10.1371/journal.pone.0105900 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kang D, Kim IR, Park YH, Im YH, Zhao D, Guallar E, Ahn JS, Cho J (2019) Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT). Support Care Cancer:1–9.  https://doi.org/10.1007/s00520-019-04982-z
  14. 14.
    Chan DF-MA, Ciccolini K, Samuels A, Lacouture M (2018) Impact of persistent anticancer therapy–induced alopecia on quality of life. J Am Acad Dermatol 73(3):AB160Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Jenna R. Stoehr
    • 1
  • Cory Kosche
    • 1
  • Jennifer N. Choi
    • 1
    • 2
    Email author
  1. 1.Department of DermatologyNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Robert H. Lurie Comprehensive Cancer CenterNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations